Apnimed

Apnimed is a late-stage clinical-stage pharmaceutical company headquartered in Cambridge, Massachusetts, developing novel oral drug therapies for sleep-related breathing disorders. Its lead candidate AD109 (Oxnimbi) is a fixed-dose combination of an anti-muscarinic and a selective norepinephrine reuptake inhibitor, designed to improve upper-airway muscle activity and treat an underlying neuromuscular cause of obstructive sleep apnea (OSA) rather than manage it mechanically. The company was founded in 2017, partners with Shionogi through the Shionogi-Apnimed Sleep Science (SASS) joint venture, and had a New Drug Application for AD109 accepted by the FDA in 2026. Apnimed is a drug developer, not a software vendor: it publishes no developer portal, API documentation, or machine-readable API artifacts.

Apnimed is profiled on the APIs.io network. Tagged areas include Company, Pharmaceuticals, Biotechnology, Health Care, and Life Sciences.

Apnimed’s developer surface includes engineering blog, support, and 13 more developer resources.

🌐 Visit website 📡 Source on GitHub

12.2/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0

0 APIs

CompanyPharmaceuticalsBiotechnologyHealth CareLife SciencesSleep MedicineClinical Trials

Kin Score

Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0

Composite quality — 12.2/100 · minimal

Contract Quality 0.0 / 21

Developer Ergonomics 1.1 / 17

Commercial Clarity 3.6 / 17

Operational Transparency 0.0 / 11

Governance 0.0 / 10

Discoverability 4.9 / 9

Regulatory Posture 2.6 / 15

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 10

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

A2A Agent Card 0 / 8

Dry-Run / Simulate Mode 0 / 4

Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.

The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/apnimed: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 2

Status, limits, changes, and where to get help

Support

Support

PressReleases

PressReleases

Commercial 2

Pricing, plans, and the legal terms of use

TermsOfService

TermsOfService

PrivacyPolicy

PrivacyPolicy

Company 7

The organization behind the API

Website

Website

About

About

Blog

Blog

InvestorRelations

InvestorRelations

Careers

Careers

LinkedIn

BlogFeeds

BlogFeeds

Scroll for all 7

Other 2

Properties that don't map to a standard resource type

SecondaryMarket

SecondaryMarket

Research

Research

Source (apis.yml)

aid: apnimed
name: Apnimed
description: 'Apnimed is a late-stage clinical-stage pharmaceutical company headquartered in Cambridge, Massachusetts, developing
  novel oral drug therapies for sleep-related breathing disorders. Its lead candidate AD109 (Oxnimbi) is a fixed-dose combination
  of an anti-muscarinic and a selective norepinephrine reuptake inhibitor, designed to improve upper-airway muscle activity
  and treat an underlying neuromuscular cause of obstructive sleep apnea (OSA) rather than manage it mechanically. The company
  was founded in 2017, partners with Shionogi through the Shionogi-Apnimed Sleep Science (SASS) joint venture, and had a New
  Drug Application for AD109 accepted by the FDA in 2026. Apnimed is a drug developer, not a software vendor: it publishes
  no developer portal, API documentation, or machine-readable API artifacts.'
image: https://apnimed.com/wp-content/themes/apnimed/favicon/android-icon-192x192.png
url: https://raw.githubusercontent.com/api-evangelist/apnimed/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: profile
x-tier-reason: no-api-surface
specificationVersion: '0.20'
created: '2026-08-06'
modified: '2026-08-06'
tags:
- Company
- Pharmaceuticals
- Biotechnology
- Health Care
- Life Sciences
- Sleep Medicine
- Clinical Trials
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/apnimed-domain-security.yml
- type: Website
  url: https://apnimed.com/
- type: About
  url: https://apnimed.com/about/
- type: Blog
  url: https://apnimed.com/news/
- type: Support
  url: https://apnimed.com/contact-us/
- type: TermsOfService
  url: https://apnimed.com/terms-and-conditions/
- type: PrivacyPolicy
  url: https://apnimed.com/privacy-policy/
- type: InvestorRelations
  url: https://ir.apnimed.com/
- type: Careers
  url: https://apnimed.com/careers/
- type: LinkedIn
  url: https://www.linkedin.com/company/apnimed
- type: SecondaryMarket
  url: https://forgeglobal.com/apnimed_stock/
- type: BlogFeeds
  url: https://apnimed.com/feed/
- type: PressReleases
  url: https://apnimed.com/news/
- type: Research
  url: https://apnimed.com/publications/
- type: LLMsTxt
  url: llms/apnimed-llms.txt
x-enrichment:
  date: '2026-08-06'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: Apnimed is a clinical-stage drug developer whose product is an oral pill (AD109) for obstructive sleep apnea, so
    there is no software surface to expose; apnimed.com is a WordPress marketing site whose full Yoast sitemap lists 24 pages
    and not one developer, API, or documentation page, and api./docs./developer.apnimed.com do not resolve in DNS.
  evidence:
  - url: https://apnimed.com/openapi.json
    status: 404
  - url: https://apnimed.com/llms.txt
    status: 404
  - url: https://apnimed.com/.well-known/agent-card.json
    status: 404
  - url: https://apnimed.com/.well-known/security.txt
    status: 404
  - url: https://api.apnimed.com/openapi.json
    status: 0
  - url: https://ir.apnimed.com/llms.txt
    status: 404
  checked: '2026-08-06'